​

Drugs Made In America Acquisition Stock (NASDAQ:DMAA)

OwnershipFinancialsChart

Previous Close

$10.47

52W Range

$9.98 - $10.49

50D Avg

$10.43

200D Avg

$10.31

Market Cap

$351.26M

Avg Vol (3M)

$65.06K

Beta

3.19

Div Yield

-

DMAA Company Profile

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Show More

Industry

Shell Companies

Sector

Financial Services

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

Jan 27, 2025

Website

DMAA Performance

DMAA Financial Summary

Dec 24
Revenue-
Operating Income$-479.73
Net Income$-479.73
EBITDA-
Basic EPS$-0.06
Diluted EPS$-0.06

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MLACMountain Lake Acquisition Corp.
ALFCenturion Acquisition Corp.
LOKVLive Oak Acquisition Corp. V Class A Ordinary Shares
SIMASIM Acquisition Corp. I
RTACRenatus Tactical Acquisition Corp I Class A Ordinary Shares
TACOBerto Acquisition Corp.
TACHTitan Acquisition Corp.
OYSEOyster Enterprises II Acquisition Corp